Ethocle Reports has published its latest Market Research Report on Restenosis – Pipeline Review, H1 2017. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse market data tables and figures.
Published On: 15-Mar-2017 | Pages: 42
Pharmaceutical and Healthcare disease pipeline guide Restenosis – Pipeline Review, H1 2017, provides an overview of the Restenosis (Cardiovascular) pipeline landscape.
Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Restenosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Restenosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Restenosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Restenosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Restenosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Restenosis (Cardiovascular).
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Global Markets Direct Report Coverage
Restenosis – Overview
Restenosis – Therapeutics Development
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Restenosis – Therapeutics Assessment
Restenosis – Companies Involved in Therapeutics Development
Bio3 Research Srl
Chrysalis BioTherapeutics Inc
Restenosis – Product Development Milestones